替诺福韦二吡呋酯降低乙肝肝硬化患者肝癌、失代偿和死亡风险
本研究在三个三级中心纳入1088例慢性乙型肝炎肝硬化患者(291例未治疗历史对照,797例接受TDF≥12个月),比较5年累积概率。TDF组肝癌、失代偿、死亡或肝移植风险均显著降低,多变量Cox回归显示TDF独立相关。
要点
- TDF治疗与肝癌风险降低独立相关(aHR 0.46)
- TDF治疗与失代偿风险降低独立相关(aHR 0.28)
- TDF治疗与死亡或肝移植风险降低独立相关(aHR 0.06)
核心结论
- 与未治疗患者相比,TDF治疗可降低慢性乙型肝炎肝硬化患者5年肝癌、肝失代偿和死亡风险。
研究设计与样本
- 研究纳入三个三级中心的慢性乙型肝炎肝硬化患者,TDF队列为连续接受TDF≥12个月者,未治疗队列为抗病毒治疗可用前的历史对照。
主要发现
- 敏感性分析显示无论肝病严重程度和既往抗病毒治疗如何,TDF治疗的风险降低一致。
临床怎么用
- 对于慢性乙型肝炎肝硬化患者,可考虑使用TDF抗病毒治疗以降低肝癌、失代偿和死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lamivudine and entecavir reduce hepatic events and death in chronic hepatitis B (CHB) patients with cirrhosis, but the impact of tenofovir disoproxil fumarate (TDF) is less well studied. AIM: To investigate the effectiveness of TDF therapy in CHB patients with cirrhosis. METHODS: We studied TDF-treated and untreated CHB patients with cirrhosis from three tertiary centres. TDF cohort included consecutive patients who received TDF for ≥12 months while the untreated cohort were historical controls receiving routine clinical care prior to the availability of anti-viral therapy. The primary outcome was 5-year cumulative probability of hepatocellular carcinoma (HCC) with secondary outcomes being hepatic decompensation and death or liver transplantation (LT). RESULTS: A total of 1088 (291 untreated and 797 TDF-treated) patients were included in the study. Five-year cumulative probabilities in untreated vs TDF-treated cohorts were 14.9% vs 9.8% for HCC (P = .07), 22.3% vs 5.9% for decompensation (P < .01) and 13.1% vs 1.1% for death or LT (P < .01) respectively. On multivariable Cox regression, TDF treatment was independently associated with reduced risks of HCC (adjusted hazard ratio [aHR] 0.46, P < .01), decompensating events (aHR 0.28, P = .01) and death or LT (aHR 0.06, P < .01). On sensitivity analyses, these risk reductions with TDF treatment were consistently demonstrated regardless of severity of liver disease and prior anti-viral treatment. TDF treatment led to sustained improvements in most validated prognostic scores for predicting HCC, decompensation and death. CONCLUSIONS: Compared to untreated patients, TDF treatment reduces the risks of HCC, hepatic decompensation and death in CHB patients with cirrhosis at 5 years.
引用
- Liu K, Choi J, Le A, et al. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. Aliment Pharmacol Ther. 2019. PMID: 31524304. doi:10.1111/apt.15499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。